This free white paper discusses the early development considerations when considering cost-effective ways to de-risk biomarker clinical trials.
Using a diagnostic assay during early drug development decreases enrolment costs and shortens trial timelines by focusing on target patient population.
Trial failure is also minimised as the right patient, treatment, time and dose are identified. In addition, drug and assay development timelines are coordinated such as for applications for accelerated approval or breakthrough designation.
However, the assay takes time to develop, so coordination is key. It also requires an additional investment in the early development phase.
Download this white paper to find out more.
Thank you.Please check your email to download the white paper.